You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
'Inflammation book' is published under the aegis of the Society of Inflammation Research, which is an endeavor to disseminate knowledge about inflammation. This book provides the latest information on cutting-edge research concerning inflammation, its fundamentals including the direct and indirect determinants, besides the advanced management protocols employed in clinical practice. This volume of the book deals with basic molecular aspects of antibody response in various inflammatory conditions like sepsis, organ transplantation, role of lipid metabolism in inflammation, followed by detailed description on certain disease entities caused due to inflammation. Each topic is dealt in detail i
In this volume author has discussed about leflunomide. Leflunomide (LEF) confers a different mechanism of action than other existing disease modifying anti-rheumatic drugs (DMARD). The suppressing joint inflammation and retarding the progression of structural damage. There are many myths and controversies surrounding the use of LEF in RA. The present volume on LEF will serve as a quick reference guide to rheumatologists and clinicians. To enhance the utility of the handbook, the author has attempted to clarify almost all the possible clinical scenarios related to LEF prescription and also included the most up-to-date information and evidence-based guidelines on the drug. This edition is uniquely valuable educational resource on LEF, thereby to use the drug safely and effectively.
Rheumatoid arthritis is an inflammatory autoimmune disease, which may result in severe disabilities and deformities if not diagnosed early and managed with adequate dose of DMARDs. The early diagnosis is often impaired by initial atypical presentations and its close mimic to other autoimmune rheumatic diseases. From the point of diagnosis to treatment of the disease, the practicing rheumatologist confronts various challenges. With an intention to address such challenges and to develop a quick reference guide for all clinicians, author started publishing the question and answer series on rheumatoid arthritis since 2012. The answers provided are substantiated by well-accepted guidelines, literature evidence and clinical experience. These answers can assist decision making in diverse clinical circumstances. Author has made a sincere attempt to make the complied volume more scenario-oriented.
This book purports to provide the latest information on cutting-edge research concerning inflammation, its fundamentals including the direct and indirect determinants, besides the advanced management protocols employed in clinical practice. This volume of the book widens the horizon delving deeper to understand the molecular aspects of inflammation such as role of memory T cells, cytokines, concept of self-tolerance and autoimmunity.
The author has attempted to bring observations into this book with reference to management decision making while treating RA. The major difference observed was the counselling and the assertive suggestion and advice. The dosage prescribed and the combinations attempted are the usual factors responsible for failure. The author has discussed in this volume on how to counsel the patients of RA and how to manage the symptoms related to RA.
The seventh volume of the book series focuses on the use of tofacitinib for managing rheumatoid arthritis (RA). The book may serve as a clinical guide to assist healthcare professionals for using the drug safely and effectively, thereby to improve the prescription practice. In the past one decade, tofacitinib has emerged as a potent target synthetic (ts) DMARD for managing RA. The availability of the generic form in global markets has improved its accessibility and clinical use. The drug though very effective in the management of RA, has narrow therapeutic to toxicity ratio. The drug needs to be prescribed with caution. There are set guidelines and pre-introduction evaluation of the drug for...
Volume -5 focuses on two drugs ‘Sulfasalazine’ and ‘Hydroxychloroquine’. They have been in clinical use for over 50 years and they were the recommended first choice for managing rheumatoid arthritis prior to the introduction of methotrexate aggressive therapy and pyramidal approach in DMARD prescription. The lack of further studies and probable bias in the clinical trials toward biologics have made these drugs less preferred in routine clinical practice. The present volume provides the most up-to-date information regarding the current status, safety and efficacy, adverse events, and the precautionary measures to be adopted while prescribing these drugs
The third volume of the book series has focused on the use of methotrexate (MTX) for managing rheumatoid arthritis (RA). The book is written with an intention to develop a clinical guide to assist healthcare professionals for using the drug safely and effectively, thereby to improve the prescription practice. In the past two decades, MTX has emerged as the gold standard DAMRD treatment for managing RA. The prescription of MTX has also changed significantly based on the accumulated experience from clinical practice. However, the assessment of the prescription patterns indicates the lack of evidence-based guidelines for prescribing the drug. The guidelines and recommendations provided in this ...